Stallergenes Greer announced on July 3, 2025, the transition of promotional activities for its sublingual immunotherapy tablet Actair® from Shionogi to CEOLIA Pharma in Japan. The move marks the end of a 15-year licensing agreement established in 2010, during which Shionogi was responsible for developing, registering, and commercializing the house dust mite-induced allergic rhinitis treatment in the Japanese market.
Partnership Transition Details
CEOLIA Pharma has been appointed as Stallergenes Greer's new promotional partner in Japan effective July 3, 2025. To ensure continuity of patient care and healthcare professional support, Shionogi will maintain its role as Marketing Authorisation Holder (MAH) during the transition period. The company will continue handling importation, manufacturing, and distribution of Actair® while providing active support to CEOLIA through knowledge transfer and operational assistance.
Treatment Focus and Market Impact
Actair® represents a specialized approach to treating house dust mite-induced allergic rhinitis through sublingual immunotherapy. The treatment addresses respiratory allergies, a significant health concern affecting quality of life for patients. Stallergenes Greer, headquartered in Baar, Switzerland, specializes in allergy diagnosis and treatment through allergen immunotherapy products and services, with over 100 years of expertise in the field.
Company Positioning and Future Outlook
The transition reflects Stallergenes Greer's strategic approach to expanding access to allergen immunotherapy treatments. CEOLIA, founded in 2010, focuses specifically on otolaryngology (ENT) healthcare needs, developing and marketing ethical drugs, medical devices, and diagnostic reagents in the ENT field. The company's mission centers on serving and contributing to people's health and happiness.
Stallergenes Greer acknowledged Shionogi's sustained commitment to improving allergy care in Japan throughout their partnership. The company expressed confidence in CEOLIA as a trusted new partner to further advance allergen immunotherapy access and continue improving quality of life for patients with respiratory allergies.
The global reach of Stallergenes Greer's products extends to over 40 countries, supported by more than a century of innovation in allergy treatment. Shionogi maintains its commitment to addressing areas of high unmet medical needs, striving to deliver innovative treatments that improve quality of life for patients and their families.
